Writing a GVD that avoids common omissions

How a well-written GVD can save time and resources for pharmaceutical market access teams and help accelerate patient access.

Our research shows that up to 30% of global HTA template requirements may not be met by a traditional GVD.

This free download identifies 5 common omissions that, if met by global data, could improve GVD effectiveness for local affiliates, save time, and help accelerate patient access.

If you have any questions about how to write a great GVD, or want some support from our GVD services, we would be happy to help. Here is what our clients say about us:

The GVD rollout was an overwhelming success. Our affiliates told us that this GVD was the best they had ever seen. Thanks for making this important deliverable a truly quality document.”

Market Access Manager, top-5 pharmaceutical company

“The GVD was high-quality starting material, thank you.”

Senior Manager, Market Access, top-5 pharmaceutical company

“Throughout the GVD development the support and partnership was great. The market access accomplishment in the UK with NICE is absolutely exceptional!”

Therapeutic Area Head, leading pharmaceutical company

FREE Whitepaper

Fill in your details to download your FREE Whitepaper

Free download

Latest insights

Market access for biotechnology

Menopause and work: initiatives to support employees

LGBTQ+ History Month in the workplace